Modality
Small Molecule
MOA
KRASG12Di
Target
CD19
Pathway
JAK/STAT
PSPT2DPAH
Development Pipeline
Preclinical
~Oct 2020
→ ~Jan 2022
Phase 1
Apr 2022
→ Nov 2027
Phase 1Current
NCT03039668
628 pts·PSP
2025-04→2027-11·Active
NCT06801464
694 pts·T2D
2022-04→2027-07·Not yet recruiting
1,322 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-07-071.3y awayPh2 Data· T2D
2027-11-151.6y awayPh2 Data· PSP
Trial Timeline
Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
P1/2
Not yet…
P1/2
Active
Catalysts
Ph2 Data
2027-07-07 · 1.3y away
T2D
Ph2 Data
2027-11-15 · 1.6y away
PSP
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03039668 | Phase 1/2 | PSP | Active | 628 | EASI-75 |
| NCT06801464 | Phase 1/2 | T2D | Not yet recr... | 694 | CfB |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-8662 | Pfizer | NDA/BLA | CD19 | |
| NVS-6974 | Novartis | Preclinical | CD19 | |
| Voxarasimod | Merck & Co | Phase 1/2 | CD19 | |
| Doxarasimod | Merck & Co | NDA/BLA | FGFR | |
| Zanusertib | AbbVie | Approved | PCSK9 | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| Terarasimod | Krystal Biotech | Phase 1/2 | PI3Kα | |
| Tirarelsin | TG Therapeutics | NDA/BLA | CD19 | |
| DAW-5540 | Day One Bio | Phase 2 | AHR |